Fierce Biotech Names HiFiBiO TherapeuticsHiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023
2023-08-28
免疫疗法临床1期
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising early-stage biotechnology companies in the industry.
This press release features multimedia. View the full release here:
“HiFiBiO TherapeuticsHiFiBiO Therapeutics is at the forefront of harnessing single-cell insights to bring innovative immunomodulatory therapeutics into the clinic,” remarked Liang Schweizer, PhD, Founder, Chairperson, and CEO of HiFiBiO TherapeuticsHiFiBiO Therapeutics. “The Fierce 15 recognition reflects our passionate dedication to patients with unmet medical needs, and further highlights our unique Drug Intelligence Science (DIS®) approach to enhance the probability of success of immunotherapy from targets to drugs to patients.”
HiFiBiO TherapeuticsHiFiBiO Therapeutics is differentiated by its pioneering DIS® approach which combines a proprietary microfluidic single-cell platform with advanced AI/ML-based data analytics to gain unprecedented insights into human disease biology. Through this high-resolution translational approach, HiFiBiO Therapeutics has advanced three programs into Phase 1 trials, a first-in-class TNFR2 agonistTNFR2 agonist (HFB200301, NCT05238883), a best-in-class BTLA antagonist (HFB200603, NCT05789069), and a 2nd generation OX40 agonistOX40 agonist (HFB301001, NCT05229601).
Since 2017, HiFiBiO TherapeuticsHiFiBiO Therapeutics has built a sustainable pipeline targeting key mechanisms of immune modulation, with eight clinical candidates discovered, mainly across oncology and autoimmune diseases. With more than $180M in financing from world-class investors and an experienced top-tier scientific and clinical team, HiFiBiOHiFiBiO is well-positioned to deliver effective therapeutic solutions for patients globally.
“For the past 21 years, we have assessed hundreds of early-stage companies for inclusion in the 'Fierce 15' special report. To curate this list, we consider a diverse range of factors, including the robustness of their technology, partnerships, venture support and their competitive positioning within the market,” said Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare. “Our special report celebrates innovation and creativity in the face of intense competition.”
About Fierce Biotech
Fierce Biotech is the biotech industry’s daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories.
About HiFiBiO TherapeuticsHiFiBiO Therapeutics
HiFiBiO TherapeuticsHiFiBiO Therapeutics is a clinical stage global biotech pioneering a unique high-resolution translational solution (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiOHiFiBiO gains an unprecedented understanding of immune modulation in human diseases which drives a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiOHiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® approach. Additional information can be found at .
HiFiBiO TherapeuticsHiFiBiO Therapeutics, HiFiBiO TherapeuticsHiFiBiO Therapeutics logo, and DIS® are trademarks of HiFiBiOHiFiBiO and its affiliates.
View source version on businesswire.com:
Contacts
Media
Vincent Tse
Senior Director of Staff and Strategy
HiFiBiO Therapeutics
media@hifibio.com
Source: HiFiBiO TherapeuticsHiFiBiO Therapeutics
Smart Multimedia Gallery
Photo
View this news release and multimedia online at:
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。